WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

Obesity Clinical Trial

— WAVe  

Official title:

A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03297359
• Other study ID #: WAVe-001
• Status: Terminated
• Phase: Phase 2
• Start date: March 21, 2018
• Est. completion date: November 30, 2023

Study information

• Verified date: January 2024
• Source: Ottawa Hospital Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cancer patients that develop blood clots are treated with low molecular weight heparin injections (LMWH). One kind of these LMWHs, dalteparin, has its dose determined based on a patient's weight using a formula of 200 international units (IU) per kilogram (kg). The current dosing of dalteparin approved by Health Canada has a maximum daily dose of 18 000 IU/day which is weight-adjusted for patients up to 90 kg. Any patient weighing more than 90 kg would take the same dosage regardless of their weight. The aim of this study is to assess the safety of using weight-adjusted dalteparin in cancer-associated venous thromboembolism patients that weigh more than 90 kg.

Description:

The study is designed as a multicentre prospective cohort study with multiple Canadian sites. It will be initiated at The Ottawa Hospital prior to being offered externally. After obtaining informed consent, and confirming eligibility, participants weighing more than 90 kg with acute cancer-associated thrombosis will be treated with therapeutic weight-adjusted dalteparin (subcutaneous once daily injection, or twice daily, if the conditions of the participant do not allow once daily injection as per clinical judgement) beginning at enrolment (within 12 hours) and continuing until Day 30 visit. Subjects will receive therapeutic doses of dalteparin at a dose of approximately 200 IU/kg SC daily (up to 33,000 IU) for one month. Following this study period of 30 days (± 4 days), patients will be followed for 5 months. During the follow-up period, each patient will pursue his/her treatment as per usual standard treatment protocols provided at each institution. Treatment used and clinical outcomes will be collected at the end of the follow-up period. The majority of Canadian Thrombosis specialists use weight adjusted dosing of dalteparin in patients weighing more than 90 kg with cancer-associated VTE. No expert recommends capping the dose of dalteparin to 18,000 IU in patients weighing over 90 kg as suggested by the product monograph. However, the risk of major bleeding episodes in patients over 90 kg receiving weight-adjusted LMWH remains unclear. The estimated rate of major bleeding episodes of patients with cancer associated VTE (Mean weight 79.1 kg) managed with therapeutic dose of dalteparin is 3.6% (95% CI: 1.9 to 6.2). We hypothesize that the rate of major bleeding events will be similar in patients (> 90 kg) with cancer-associated VTE treated with dalteparin 200 IU/kg daily (up to 33,000 IU). We plan to recruit 150 patients in this cohort study. We expect 6 major bleeding events. This would provide us with an overall bleeding event of 4% with an upper bound of the confidence interval of 8.5%). An informal survey of Canadian thrombosis expert has demonstrated that clinicians would feel reassured and continue to use weight-adjusted dalteparin in cancer patients weighing more than 90kg if the upper bound of the 95% confidence interval is less than 9% (i.e. < 3% possible absolute rate difference).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 92
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Known pathologically-confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin),

2. Confirmed symptomatic or incidental deep vein thrombosis requiring treatment, or confirmed symptomatic or incidental pulmonary embolism of a segmental or larger pulmonary artery,

3. Weight > 90 kg,

4. Age =18 years,

5. Hemoglobin = 80 g/L,

6. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form.

Exclusion Criteria:

1. Acute VTE managed with thrombectomy, insertion of an inferior vena cava filter or with the use of thrombolytic agents,

2. More than 72 hours pre-treatment with therapeutic dosage of other LMWH, direct oral anticoagulants or vitamin K antagonists prior to enrolment to manage the current VTE event (unless the participant has been treated with weight-adjusted doses of commercial dalteparin in consistency with the dosing regime outlined in the protocol up to Day 7 visit [±2 days]),

3. Contraindication to heparin therapy:

1. history of heparin induced thrombocytopenia (HIT) as reported by patient,

2. platelet count of less than 50 x 109/L,

3. actively bleeding,

4. reported history of severe uncontrolled hypertension,

5. documented peptic ulcer within 6 weeks,

6. reported history of severe hepatic failure,

7. creatinine clearance of < 30 ml/min as calculated by the Cockcroft-Gault formula,

8. heparin allergy,

9. Other contraindication to anticoagulation.

4. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or 4 at the time of study enrolment,

5. Life expectancy < 1 month,

6. Women of childbearing age without proper contraceptive measures and women who are pregnant or breast feeding,

7. Participating in another interventional trial that may result in co-intervention or contamination (to be determined by sponsor),

8. Unable/unwilling to provide informed consent.

Related Conditions & MeSH terms

• Cancer
• Obesity
• Thromboembolism
• Venous Thromboembolism

Intervention

Biological:
• Dalteparin
daily subcutaneous injection of weight-adjusted dalteparin

Locations

Country	Name	City	State
Canada	Alberta Health Services	Edmonton	Alberta
Canada	Nova Scotia Health Authority	Halifax	Nova Scotia
Canada	Juravinski Hospital	Hamilton	Ontario
Canada	The Ottawa Hospital	Ottawa	Ontario
Canada	Toronto General Hopsital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute	Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major bleeding episode	Fatal bleeding, and/or,; Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or,; Bleeding causing a fall in hemoglobin level of =20 g/L, or leading to transfusion of =2 units of whole blood or red cells.	up to day 30
Secondary	Clinically relevant non major bleeding events	As overt bleeding episodes not meeting the inclusion for major bleeding but associated with one of the following: Medical intervention,; An unscheduled contact with a physician,; Temporary cessation of anticoagulant treatment.	up to day 30
Secondary	Minor bleeding events	Overt bleeding not meeting the major bleeding or clinically-relevant non-major bleeding definitions	up to day 30
Secondary	Recurrent VTE events	Recurrent deep vein thrombosis; Recurrent Pulmonary embolism	Up to day 180
Secondary	Overall mortality	Death	Up to day 180
Secondary	Bioaccumulation of study drug	Trough anti-Xa levels measured at Day 7 and Day 30 follow-up visits will be generated for the once and twice-daily dosing regimen	Up to day 30